Philips Healthcare and Paige are joining to deliver artificial intelligence (AI) applications for cancer to pathology laboratories.
The goal is to help pathologists identify, quantify, and characterize cancer in tissue samples and make precise diagnoses more efficiently using machine-learning methods and real-time review.
Philips markets the IntelliSite digital pathology system, and Paige has been developing organ-specific modules for AI-guided cancer detection and tumor segmentation. In November, the Paige Prostate module for prostate cancer detection and Paige Insight AI-native digital pathology slide viewer received the CE Mark for primary diagnosis.
Philips intends to offer the Paige Prostate module to European pathology labs in 2020, followed by AI solutions for other markets and additional disease areas.
Some pathology laboratories have already converted their glass slide-based workflow to digital technology, using the IntelliSite digital pathology solution. Through the collaboration, in cases where digital images are available, the Paige Prostate software will kick in to assist with the detection and localization of prostate cancer.